Navigation Links
In the quest for safer treatment for systemic lupus erythematosus
Date:6/17/2014

This news release is available in Spanish.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. It can affect various organs, in particular, the skin, joints and kidneys although it displays great variability in extent and seriousness depending on the patient. Approximately nine out of every ten patients are female and it appears in one woman in every thousand.

As Dr Guillermo Ruiz-Irastorza, head of the Autoimmune Disease Research Unit of the Hospital Universitario Cruces, explained, traditionally lupus has been treated mostly with glucocorticoids (prednisone), despite the fact that its severe side effects have been known for years. "We doctors knew that administering high doses of prednisone in an ongoing way caused irreversible damage like osteoporosis, avascular necrosis of bone, diabetes or cataracts. However, the tendency was to accept these side effects as an inevitable price to pay in exchange for controlling the disease".

Yet recent studies by this same group indicate that lower doses of glucocorticoids could be just as effective. What is more, in more serious forms, pulsed therapy, in other words, the intermittent intravenous administering of high doses is highly effective and probably does not lead to so many adverse effects.

So the researchers at the Hospital Universitario Cruces decided to study the relation between treatment with prednisone administered orally over 4 years from the moment of diagnosis and the damage built up over the first 5 years. To complete the study, they also looked at the effect of another glucocorticoid, methylprednisolone, administered intravenously at high doses and intermittently, at the moments when the disease manifests itself with increased severity.

230 patients, 206 of whom were women, took part in the study. The average age when they were diagnosed with lupus was 35.75 years.

"We saw that by the end of the fourth year most of them, 80%, had been treated with prednisone at some point, and by the fifth year nearly 4 out of every 10, 37.8%, had developed damage," pointed out Dr Ruiz-Iraztorza. Significantly, the patients with damage had received higher doses of prednisone (10.4 mg/day as opposed to 6 mg/day in the patients without damage). In the specific study of the damage that could be directly attributed to the use of glucocorticoids, the results were similar, with average daily doses of 11 vs. 7 mg/day, respectively. And it does not stop there. As previous studies had suggested, they proved that the association with damage began with average doses of 7.5 mg/day. "In other words, above that dose, permanent side effects may appear." By contrast, pulsed methylprednisolone therapy was not associated with any kind of damage.

Anti-malarial drugs for treating lupus

The research carried out by the group at the Hospital Universitario Cruces has been published in the specialised journal Rheumatology. In fact, these results have confirmed that the guidelines used in the Auto-immune Disease unit of the Hospital Universitario Cruces for several years are good. Dr Ruiz-Irastorza stresses that the background treatment in patients with SLE has to be anti-malarial drugs, specifically hydroxychloroquine, since, as he maintains, "it has been proven that they are more effective in the long term than glucocorticoids for controlling lupus and, at the same time, they have far fewer side effects. The role of the latter needs to be restricted to managing periods during which the disease flares up."

"The beneficial effect of anti-malarial drugs on SLE was discovered by accident during the Second World War," explained the doctor. "In any case, as prolonged background treatment they were seen to be ideal for controlling lupus, even as a monotherapy in many patients with proven effects on long-time survival. So we reserve glucocorticoids to be administered when the disease flares up, and we know that in more serious cases we can administer pulsed methylprednisolone safely and effectively. For maintenance treatment, the prednisone dose must not exceed 5 mg/day so on occasions we have to add other immunosuppressive drugs. We believe that these combined guidelines that we use constitute a safer and more effective alternative for patients with SLE."


'/>"/>

Contact: Matxalen Sotillo
komunikazioa@ehu.es
34-688-673-770
University of the Basque Country
Source:Eurekalert  

Related medicine news :

1. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
2. When to have kids: A complex question for hazel dormice
3. Weirdest hCG Questions Revealed
4. New Polar RCX3 Heart Rate Monitor Versus Suunto Quest
5. Progress in quest to reduce use of radiation in treatment of pediatric Hodgkin lymphoma
6. Medtronic Infuse Bone Graft Questioned As Allegations Unfold – Bisnar
7. Chase Attorneys Offer Free Consultations
8. HCOs find risks & opportunities in quest for reduced costs & improved quality
9. Health care organizations quest for reduced costs and improved quality
10. Study questions value of calcium and vitamin D supplements
11. Study Questions Guidelines on Radiation for Older Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
In the quest for safer treatment for systemic lupus erythematosus
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
Breaking Medicine Technology: